Parallel Advisors LLC Purchases 749 Shares of Eli Lilly and Company $LLY

Parallel Advisors LLC lifted its position in Eli Lilly and Company (NYSE:LLY) by 2.6% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 29,966 shares of the company’s stock after buying an additional 749 shares during the period. Eli Lilly and Company comprises 0.6% of Parallel Advisors LLC’s portfolio, making the stock its 27th largest holding. Parallel Advisors LLC’s holdings in Eli Lilly and Company were worth $32,204,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in LLY. Maryland Capital Advisors Inc. purchased a new position in shares of Eli Lilly and Company during the fourth quarter valued at approximately $25,000. Vermillion & White Wealth Management Group LLC raised its holdings in shares of Eli Lilly and Company by 84.2% during the third quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock valued at $27,000 after purchasing an additional 16 shares during the last quarter. 10Elms LLP raised its holdings in shares of Eli Lilly and Company by 33.3% during the third quarter. 10Elms LLP now owns 40 shares of the company’s stock valued at $31,000 after purchasing an additional 10 shares during the last quarter. E Fund Management Hong Kong Co. Ltd. raised its holdings in shares of Eli Lilly and Company by 342.9% during the fourth quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock valued at $32,000 after purchasing an additional 24 shares during the last quarter. Finally, Miller Global Investments LLC purchased a new position in shares of Eli Lilly and Company during the fourth quarter valued at approximately $33,000. 82.53% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on LLY shares. CICC Research boosted their price objective on shares of Eli Lilly and Company from $1,060.00 to $1,107.00 and gave the company a “neutral” rating in a report on Wednesday, February 11th. HSBC cut shares of Eli Lilly and Company from a “hold” rating to a “reduce” rating and decreased their price objective for the company from $1,070.00 to $850.00 in a report on Tuesday, March 17th. Guggenheim reissued a “buy” rating and set a $1,183.00 price objective on shares of Eli Lilly and Company in a report on Tuesday, May 5th. Freedom Capital raised shares of Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Tuesday, February 10th. Finally, Daiwa Securities Group boosted their price objective on shares of Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the company a “buy” rating in a report on Wednesday, February 18th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $1,227.00.

Eli Lilly and Company Stock Up 4.3%

Shares of LLY stock opened at $1,125.00 on Friday. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,149.10. The stock has a market cap of $1.06 trillion, a P/E ratio of 39.96, a P/E/G ratio of 1.18 and a beta of 0.53. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26. The company has a 50 day simple moving average of $970.24 and a two-hundred day simple moving average of $1,012.19.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, April 30th. The company reported $8.55 EPS for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The business had revenue of $19.80 billion during the quarter, compared to analysts’ expectations of $17.82 billion. During the same period in the prior year, the company earned $3.34 earnings per share. The firm’s revenue was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, research analysts expect that Eli Lilly and Company will post 35.8 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend is Friday, May 15th. Eli Lilly and Company’s dividend payout ratio is currently 24.58%.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Eli Lilly signed a collaboration and licensing deal with Ascidian Therapeutics worth up to $1.9 billion to develop RNA-based kidney-disease therapies, reinforcing its strategy of using GLP-1 cash flow to broaden the pipeline. Eli Lilly, Ascidian Sign $1.9 Billion Kidney-Disease Treatment Deal
• Positive Sentiment: Management signaled that more M&A may be coming, which investors view as a way to reduce reliance on obesity drugs and build new long-term growth engines. Eli Lilly’s top dealmaker says don’t be surprised to see more M&A that pushes Lilly into new areas
• Positive Sentiment: Multiple articles highlighted Lilly as a stock to own, citing its strong GLP-1 franchise and broader pipeline momentum across gene editing, vaccines, and cancer. 3 Reasons Eli Lilly Remains a Buy
• Neutral Sentiment: Weight Watchers expanded access to its program through LillyDirect, which reinforces Lilly’s ecosystem around GLP-1 drugs but is not a direct financial catalyst on its own. Weight Watchers Expands Reach Through LillyDirect Partnership (WW)
• Neutral Sentiment: Technical/market commentary also turned favorable, with one note saying Lilly flashed two buy signals, adding to the bullish sentiment around the name. Eli Lilly, IBD Stock Of The Day, Flashes Two Buy Signals
• Negative Sentiment: Broader market weakness from a selloff in AI/tech sentiment could create some cross-asset pressure, though this is not specific to Lilly’s fundamentals. Stock Market Today, June 4: Broadcom Drags on Nasdaq at Midday

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.